El gobernador de California, Gavin Newsom, que aspira a presentarse en las elecciones presidenciales, ha enfurecido tanto a demócratas como a republicanos por su posición sobre la atención médica para los inmigrantes en su estado. La situación revela el delicado camino político que tiene por delante. Por segundo año, el demócrata pidió a los legisladores…
This brief explains the limitations of early data in understanding the impact of the expiration of enhanced premiums tax credit on ACA enrollment. It also provides a timeline of when more complete data will become available.
California Gov. Gavin Newsom, who is eyeing a presidential bid, has incensed both Democrats and Republicans over immigrant health care in his home state, underscoring the delicate political path ahead. For a second year, the Democrat has asked state lawmakers to roll back coverage for some immigrants in the face of federal Medicaid spending cuts…
NEW ORLEANS — Sarah Hess started taking her toddler, Josie, to Mickey Markey Playground in 2010 because she thought it would offer a refuge from lead. After a routine doctor visit revealed Josie had lead poisoning, Hess quickly traced the source to the crumbling paint in her family’s century-old home in the Bayou St. John…
FDA’s January 2026 draft guidance on Bayesian methodology in drug and biologics trials signals a clear willingness to see Bayesian methods used for regulatory decisionmaking around clinical trials. The guidance lays out how sponsors (i.e., pharmaceutical manufacturers) should pre-specify priors, success criteria, and simulations so that Bayesian designs remain interpretable, control error rates when needed,…
Jake Leach became DexCom’s chief executive on January 1 and is trying to write the turnaround story of this innovative medtech company. One story to tell is how CGMs should be a no-brainer for type 2 diabetes patients on GLP-1 weight loss drugs. The post DexCom’s CEO Believes Diabetics On GLP-1s Should Also Wear CGMs…
The 2026 Medicare ACO landscape features expanded participation, new models like LEAD, and a focus on advanced payment tracks
Veradermics’s drug, a pill version of the topical hair loss product minoxidil, was developed with technology intended to avoid the cardiovascular risks associated with oral dosing of this compound. The first of three pivotal clinical trials is expected to yield preliminary data in the first half of 2026. The post Baldness Biotech Veradermics Prices $256M…
Wolters Kluwer Health CTO Alex Tyrrell discusses survey results that raise governance, patient safety and data security issues
Virtual women’s health provider Midi Health has reached unicorn status after raising a $100 million Series D, with investors backing its insurance-covered, direct-to-consumer model. The company is positioning itself as a long-term, virtual “hospital without walls” designed to meet women’s health needs across midlife and beyond. The post Digital Health’s Latest Unicorn: Why Investors Are…